title: Author Response: Use of Clopidogrel and Poor Visual Outcome.
authors.affiliation: East Bay Retina Consultants Inc., Oakland, California, United States;
authors.forename: Jesse J
authors.initials: JJ
authors.lastname: Jung
authors.affiliation: Department of Ophthalmology, New York University School of Medicine, New York, New York, United States;
authors.forename: Bora
authors.initials: B
authors.lastname: Chae
authors.affiliation: Vitreous Retina Macula Consultants of New York, New York, New York, United States; 4LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York, United States; 5Singapore National Eye Centre/ Singapore Eye Researc.
authors.forename: Anna C S
authors.initials: AC
authors.lastname: Tan
authors.affiliation: Weill Cornell Medical College, New York, New York, United States.
authors.forename: Samir N
authors.initials: SN
authors.lastname: Patel
authors.affiliation: Department of Ophthalmology, New York University School of Medicine, New York, New York, United States; 3Vitreous Retina Macula Consultants of New York, New York, New York, United States; 4LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and.
authors.forename: K Bailey
authors.initials: KB
authors.lastname: Freund
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D015861:Retinal Neovascularization / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A